Medium severity · published May 19, 2021
CVE-2017-17678
BMC Remedy Mid Tier 9.1SP3 is affected by cross-site scripting (XSS)
6.1
CVSS
0.6%
EPSS
No
On KEV
Description
BMC Remedy Mid Tier 9.1SP3 is affected by cross-site scripting (XSS). A DOM-based cross-site scripting vulnerability was discovered in a legacy utility.
CVSS vector
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N
Attack vector
Network
Complexity
Low
Privileges
None
User interaction
Required
Confidentiality
Low
Integrity
Low
Availability
None
Scope
Changed
Exploitation
Is it being used?
Exploit prediction (EPSS)0.6% · higher than 48% of CVEs
Exploited in the wildNo evidence yet
CISA KEVNot listed
Ransomware campaign useNot known
Affected products
Which versions
RM
Remedy Mid-tier · Bmc
9.1 · source: NVD
References
NVD
https://nvd.nist.gov/vuln/detail/CVE-2017-17678
CVE.org
https://www.cve.org/CVERecord?id=CVE-2017-17678
Release Notes
https://docs.bmc.com/docs/ars91/en/9-1-00-fixes-available-for-remedy-ar-system-security-vulnerabilities-800555806.html
Mailing List
https://seclists.org/fulldisclosure/2017/Oct/52
More from Remedy Mid-tier
9.8
CVE-2024-34399
**UNSUPPORTED WHEN ASSIGNED** An issue was discovered in BMC Remedy Mid Tier 7.6.04
9.8
CVE-2017-17674
BMC Remedy Mid Tier 9.1SP3 is affected by remote and local file inclusion
8.8
CVE-2017-17677
BMC Remedy 9.1SP3 is affected by authenticated code execution
8.8
CVE-2018-18862
BMC Remedy Mid-Tier 7.1.00 and 9.1.02.003 for BMC Remedy AR System has Incorrect Access Control in ITAM forms, as demonstrated by…
5.3
CVE-2017-17675
BMC Remedy Mid Tier 9.1SP3 is affected by log hijacking